Cognitive Improvements in Children with Prader-Willi Syndrome Following Pitolisant Treatment-Patient Reports.

Abstract

While children with Prader-Willi Syndrome (PWS), a rare genetic disease with an incidence of 1:15,000, typically present with hypotonia and hyperphagia, their lives are made more difficult by an ever-present sleepiness as well as multiple neuro-cognitive dysfunctions, including cognitive defects. We describe a case series of 3 children who were treated with the histamine 3 receptor inverse agonist pitolisant. While this first-in-class inverse agonist is approved for another orphan disease (i.e., narcolepsy with or without cataplexy), we have observed that pediatric patients with PWS prescribed pitolisant demonstrate decreased daytime sleepiness and improved cognition, as evidenced by increased processing speed and improved mental clarity. Pitolisant may represent a novel therapeutic option that might relieve substantial PWS disease burden, including cognitive disability, excessive daytime sleepiness, and poor-quality nighttime sleep.

• Authors: Lara C Pullen, Maria Picone, Litjen Tan, Charles Johnston, Holger Stark
• Journal: The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG (J Pediatr Pharmacol Ther) 2019 Mar-Apr Vol. 24 Issue 2 Pg. 166-171 ISSN: 1551-6776 [Print] United States
• PMID: 31019411 (Publication Type: Case Reports)